Fast MRI Improves Breast Cancer Screening Fast MRI Improves Breast Cancer Screening
The diagnostic speed and accuracy of breast cancer screening could be better with abbreviated MRI than with mammography, and faster protocols could also work for other conditions.Medscape Medical News
A simplified, single-view version of digital breast tomosynthesis may increase the detection of breast cancer over standard digital mammography, with lower radiation exposure, say Swedish scientists.Medscape Medical News
ConclusionCombined FFDM + DBT in the post breast cancer surveillance regimen has shown to reduce the patients' RR and to increase the CDR. FFDM + DBT had higher diagnostic accuracy than FFDM alone. FFDM + DBT ought to be a standard combination in the breast cancer surveillance in treated patients.
We examined supplemental screening (ie, MRI, ultrasound, or tomosynthesis within 6 months of screening mammogram) among a sample of 2,764 African American (AA) and 691 European American (EA) women with negative or benign screening mammograms for whom we had data from both before and after implementation of breast density notification laws in the state of Michigan.
AbstractPurposePleomorphic invasive lobular carcinoma (pILC) is a distinct morphological variant of ILC with a poorer prognosis than classical ILC (cILC). The aim of this study was to ascertain whether the conventional imaging appearances of the two entities differ.MethodsA single-center retrospective review of conventional imaging was undertaken in 150 consecutive patients with histopathologically confirmed ILC (38 pILC; 112 cILC) between April 2010 and July 2015. Mammographic and sonographic findings were evaluated using the BI-RADS lexicon by a radiologist blinded to pathology, and the findings in the two groups were co...
ConclusionsUsing USPSTF revealed preferences, 31 –74% reductions in false-positives would be required to recommend mammography screening beyond biennial screening starting at age 50. Widespread implementation of tomosynthesis and reducing recall rates to the lower end of recommended recall rates (5–12%) would provide support for expanding scre ening beyond biennial screening in women age 50.
GE Healthcare is unveiling its brand new Invenia Automated Breast Ultrasound (ABUS) 2.0 in the U.S. It is the only FDA approved “ultrasound supplemental breast screening technology,” which allows for spotting of cancerous lesions within d...
(Massachusetts Institute of Technology) Researchers from MIT and Massachusetts General Hospital have developed an automated model that assesses dense breast tissue in mammograms -- which is an independent risk factor for breast cancer -- as reliably as expert radiologists. This marks the first time a deep-learning model of its kind has successfully been used in a clinic on real patients, according to the researchers. With broad implementation, the researchers hope the model can help bring greater reliability to breast density assessments across the nation.
Three-dimensional mammography screening detected 34 percent more breast cancer tumors than the traditional process of a single image, according to a study.
AbstractBackgroundDetection of breast cancers by mammographic screening confers a survival advantage of 20 –50% compared to symptomatic presentations. The improved prognosis is only partly explained by stage migration. The distribution of the molecular subtypes of screen-detected breast cancer (SDBC) or their HER2 status has not been studied extensively. We wished to address these issues through the st udy of a large series of SDBC, with other presentations serving as controls.DesignDeidentified cases of female invasive cancer, diagnosed in Australia and New Zealand during 2005 –2015, were retrieved from the Br...
ConclusionsScreening status was strongly associated with subtype and this association persisted after adjustment for covariates including tumour stage and grade. After correcting for lead-time bias and adjusting for stage, subtype, grade and socio-demographic variables, no significant survival difference was demonstrated for women with screen-detected cancer in the 5-year period post-diagnosis. Since we are adjusting for stage, subtype and other variables, the lack of difference between these groups would be expected but has not been demonstrated in studies which do not correct for lead time bias.